ENTX - エンテラ・バイオ （Entera Bio Ltd.）

Centillion Fund increased its holding in Entera Bio.

In today’s recent session, 0.46 million shares of the Entera Bio Ltd. (NASDAQ:ENTX) have been traded, and its beta is 1.93. Most recently the company’s share price was $0.57, and it changed around $0.03 or 6.00% from the last close, which brings the market valuation of the company to $19.14M. ENTX at last check was … Entera Bio Ltd. (NASDAQ: ENTX) Could See Prices Soar In The Coming Months Read More »

The Dow Jones gained by over 50 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform.3 electroCore The Trade: electroCore, Inc. (NASDAQ: ECOR ) Director Joseph Errico bought a total of 100,000 shares at an average price of $0.24. To acquire these shares, it cost around $24.48 thousand. What’s … Full story available on Benzinga.com

Entera Bio press release (ENTX): Q3 GAAP EPS of -$0.11.As of September 30, 2022, Entera had cash and cash equivalents of $14.3 million, compared to $17.3 million as of June…

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates.

JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX ), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it will host a key opinion leader (KOL) webinar on the company''s lead asset EB613, and its potential impact on the osteoporosis market on Wednesday, September 28, 2022 at 10:00am ET. The webinar will feature presentations from KOLs John P. Bilezikian, MD, PhD, from Columbia University, Felicia Cosman, MD, also from Columbia University, and Bart L. Clarke, MD, from Mayo Clinic. The event will provide insight into the current treatment landscape and unmet medical need for post-menopausal women with osteoporosis. The discussion will focus on Entera Bio''s development of EB613, a proprietary formulation of PTH (1-34, teriparatide) as the first potential orally administered osteoanabolic treatment. Entera leadership will review their Phase 2 EB613 data, which will be followed by an overview of the Company''s proposed registrational Phase 3 plan submitted to FDA.

JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins , today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference .

https://www.investing.com/news/pro/hc-wainwright-starts-entera-bio-at-buy-432SI-2886429

Entera Bio (NASDAQ: ENTX ) reported its Q2 earnings results on Thursday, August 11, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Entera Bio beat estimated earnings by 31.25%, reporting an EPS of $-0.11 versus … Full story available on Benzinga.com

Entera Bio press release (ENTX): 1H GAAP EPS of -$0.24.Revenue of $0.11M (-59.3% Y/Y).Shares +3.68% PM

JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins , today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference .

https://www.investing.com/news/pro/hc-wainwright-starts-entera-bio-at-buy-432SI-2886429

Entera Bio (NASDAQ: ENTX ) reported its Q2 earnings results on Thursday, August 11, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Entera Bio beat estimated earnings by 31.25%, reporting an EPS of $-0.11 versus … Full story available on Benzinga.com

Entera Bio press release (ENTX): 1H GAAP EPS of -$0.24.Revenue of $0.11M (-59.3% Y/Y).Shares +3.68% PM

JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended June 30, 2022.